Radius stumbles on NDA delay

Radius Health Inc. (NASDAQ:RDUS) fell $7.67 (11%) to $61.51 on Tuesday after it said it would delay submission of an NDA for osteoporosis treatment abaloparatide-SC ( BA058-SC) to the end of 1Q16.

On the company's 3Q15 earnings call earlier this month, CEO Robert Ward said the company was on track to submit the NDA by YE15. ...